Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. Collaboration combines Telix’s expertise in radiopharmaceutical development and manufacturing with Regeneron’s leading antibody discovery/development platforms and oncology experience. Telix to receive US$40 million upfront for four initial programs with optionality on a per program basis to co-fund commercialization and profit-share or earn up to an aggr

Results from the Phase 2 IMGN853-0420 trial show an objective response rate of 62.7% and consistent safety findings with mirvetuximab soravtansine-gynx (ELAHERE®) plus carboplatin followed by a continuation of mirvetuximab soravtansine monotherapy in patients with ≥50 % folate receptor alpha (FRα)-expressing, platinum-sensitive ovarian cancer (PSOC). Findings highlight mirvetuximab soravtansine's potential across the ovarian cancer treatment continuum. Data is being presented in a late-breaking

A new study reveals that popular diabetes and weight-loss drugs like Ozempic and Wegovy may not work as effectively for about 10% of people due to specific genetic variants. These individuals appear to have a puzzling condition called “GLP-1 resistance,” where their bodies produce higher levels of the hormone targeted by these drugs—but don’t respond to it properly.More than one in four people with Type 2 diabetes use GLP-1 receptor agonists, a class of widely prescribed medications. However, ne

Researchers are launching a new project to crack the mystery of aggressive breast cancer, where predicting disease progression remains a major hurdle. By studying how tumors interact with and suppress the immune system, scientists aim to identify new biomarkers that reveal how the cancer evolves. Using real patient samples, the team hopes to turn earlier discoveries into practical clinical tools. The goal: more precise, personalized treatments that can outsmart even the most dangerous tumors.Bre

A new nanodisc-based platform lets scientists study viral proteins in a form that closely mimics real viruses, revealing how antibodies truly recognize them. This approach uncovered hidden interactions in viruses like HIV and Ebola that traditional methods missed. By recreating the virus’s membrane environment, researchers can better understand how immune defenses work. The technique could speed up the development of more effective vaccines.Viruses are highly effective at entering human cells, l

SHANGHAI, April 11, 2026 /PRNewswire/ -- At the 93rd China International Medical Equipment Fair (CMEF), Sinocare presented its latest advancements under the theme "Leading Digital Healthcare For Global Health." Bringing together cutting-edge technologies, integrated solutions, and strategic partnerships, the company demonstrated its ambition to redefine chronic disease management on a global scale. Building a Full-Stack Digital Healthcare Ecosystem Continue Reading 2026cmef Sinocare unveiled a c

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated patients with HER2-expressing, recurrent endometrial cancer, an area of high unmet medical needData demonstrated clinically meaningful antitumor activity across all HER2 expression levels and a manageable safety profile, with centrallyi HER2-tested patients showing a confirmed objective response rate of 47.9% in all evaluable patients, 49.

NEW YORK, April 11, 2026 /PRNewswire/ -- When every breath becomes a struggle for a pet, timely pet oxygen concentrator can make a meaningful difference. Until recently, this level of care was largely limited to veterinary clinics. VARON now brings veterinary-inspired respiratory support into the home with its expanded line of oxygen concentrator therapy bundles. Designed for pets in recovery, distress, or long-term respiratory care, the system delivers stable, continuous-flow oxygen in a safe

Welcome back to another edition of Endpoints Weekly. Two of the year’s major oncology conferences are coming up soon: AACR starting April 17, and ASCO at the end of May. We’re also hosting our New York City event with our parent company the Financial Times on May 14, so be sure to register for that here . Jumping into the headlines, this week saw another spate of biopharma M&A with deals from Gilead and Neurocrine. Our reporters also took a look at some of Eli Lilly and Merck’s recent acquisitio

Leukemia is adept at dodging the immune system, making it resistant to many of the newest generation of cancer immunotherapies. Now, researchers have identified a key part of the cancer’s disguise: a protein called CD43 on the surface of leukemia cells that is coated so heavily in sugar molecules that it forms a physical barrier, shielding the cells from immune attack. The findings, from scientists at the Broad Institute, Mass General Brigham, and Dana-Farber Cancer Institute, reveal a previousl